What HIV Vaccine Preparedness Teaches us about COVID Vaccine Distribution
I recently found a 1995 presentation with findings from my doctoral dissertation that are highly pertinent to COVID Vaccine trials. The study included anonymized interviews and surveys with the first high risk (#vulnerable) HIV vaccine efficacy trial participants.
No space here to share the results but I thought readers would find the questions of interest:
–Motivations for joining the trial (altruism, money, protection, access to HIV tests);
–Understanding about the vaccine trial protocol, e.g. likelihood of getting a placebo or ineffective vaccine;
–Belief they got the vaccine or placebo and reason for belief;
–Accuracy of their belief in relation to actual vaccine assignment group;
–HIV risk behaviors before and during the trial;
–Accuracy of HIV risk disclosure to vaccine trial staff;
–Receipt of HIV tests outside of the trial (e.g. unblinding them);
–Social harms/discriminatory events (e.g. due to having a vaccine-induced positive HIV test).
The study findings led to adoption of some procedures for all subsequent HIV vaccine trials such as requiring subjects to demonstrate their understanding of the risks.